Literature DB >> 29935852

Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.

Wenjuan Jiang1, Nong Yang1, Yongchang Zhang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29935852     DOI： 10.1016/j.jtho.2018.02.030

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

Review 1.  Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.

Authors:  Caiwen Huang; Qihua Zou; Hui Liu; Bo Qiu; Qiwen Li; Yongbin Lin; Ying Liang
Journal:  Curr Treat Options Oncol       Date:  2020-04-18

Review 2.  Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.

Authors:  Xing Huang; Enliang Li; Hang Shen; Xun Wang; Tianyu Tang; Xiaozhen Zhang; Jian Xu; Zengwei Tang; Chengxiang Guo; Xueli Bai; Tingbo Liang
Journal:  Front Cell Dev Biol       Date:  2020-05-06

3.  Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.

Authors:  Li Liu; Farhin Shaheed Kalyani; Haiyan Yang; Chunhua Zhou; Yi Xiong; Songlin Zhu; Nong Yang; Jingjing Qu
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.